Cargando…
Enabling Precision Medicine for Rare Head and Neck Tumors: The Example of BRAF/MEK Targeting in Patients With Metastatic Ameloblastoma
Background: Ameloblastoma is a rare head and neck tumor characterized by a high incidence of BRAF mutation providing a rationale for the use of BRAF inhibitors in patients with advanced disease. Methods: We report the case of a 26-year old female presenting with metastatic ameloblastoma. A molecular...
Autores principales: | Brunet, Maxime, Khalifa, Emmanuel, Italiano, Antoine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861385/ https://www.ncbi.nlm.nih.gov/pubmed/31781502 http://dx.doi.org/10.3389/fonc.2019.01204 |
Ejemplares similares
-
Intracranial Control With Combination BRAF and MEK Inhibitor Therapy in Patients With Metastatic Melanoma
por: Hui, Caressa, et al.
Publicado: (2022) -
Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?
por: Stagno, Anna, et al.
Publicado: (2021) -
Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report
por: Broudic-Guibert, Morgane, et al.
Publicado: (2019) -
Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
por: Stones, Clare J., et al.
Publicado: (2013) -
Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)